October 31st 2025
The rate of AF recurrence was reduced significantly and participants also experienced improvements in self-reported AF severity as well as improved cardiometabolic measures.
FDA Adds Warning About Renal Risk to Trasylol Label
December 15th 2006ROCKVILLE, Md. -- The FDA announced today it had narrowed the indications for Trasylol (aprotinin injection), a drug used control bleeding during heart surgery, partly because of belatedly revealed risks of death or serious kidney damage.
ASH: Long-term Childhood AML Survivors Do Well Overall
December 12th 2006ORLANDO -- Young patients with acute myeloid leukemia are not only surviving into adulthood but thriving well into life, albeit with an increased risk for secondary cancers or heart disease, show data from the Childhood Cancer Survivor Study.
Five-Year CML Survival with Gleevec Reaches 95%
December 7th 2006PORTLAND, Ore. -- Gleevec (imatinib) has led to an overall 60-month survival rate of 95% for chronic myeloid leukemia (CML) patients with who took the tyrosine kinase inhibitor daily, found an international study. Yet the drug doesn't cure the disease.
Sorting Out the Complexities of an Elderly Woman's Fall
December 1st 2006I enjoyed Dr Henry Schneiderman’s “What’s Your Diagnosis?” case of an elderly woman with severe facial ecchymoses from a fall. Would Dr Schneiderman elaborate on several points about that case? This woman did not trip or complain of dizziness before she fell. What caused her to fall?
Clinical Update: Idiopathic pulmonary fibrosis: Highlights from the recent literature
December 1st 2006Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with unknown etiology and a grim prognosis.1,2 The median survival is about 3 years after diagnosis or 5 years from the onset of symptoms. Its pathologic findings are those of usual interstitial pneumonia.2 Surgical lung biopsy is needed for diagnosis when these findings are not present. Usual interstitial pneumonia is the histopathologic pattern that characterizes IPF (Figure).
Diagnostic Puzzlers: A patient with an "extra" pulmonary blood vessel
December 1st 2006A 79-year-old woman with a history of atrial fibrillation was referred to the pulmonary service for preoperative evaluation for hip replacement surgery. She reported that 20 or more years ago she had been told by her physician that she has an "extra blood vessel" in the right lung. It had not caused her any difficulty. Her medical history was also notable for a heart murmur and gastroesophageal reflux disease secondary to a large hiatal hernia. She was a nonsmoker.
Chest Film Clinic: What caused this man's dyspnea, chest pain, and atrial fibrillation?
December 1st 2006A 52-year-old man presented to his primary care physician with shortness of breath for 5 days, right-sided lower thoracic back pain, and dry cough. The patient was a 15-pack-year cigarette smoker who had emigrated from China to the United States in 1989. He had no significant history of occupational exposure or tuberculosis. He had no significant weight loss, and his past medical history was otherwise unremarkable.
Drug Therapy in Elderly Patients:
December 1st 2006ABSTRACT: Age-related changes that affect drug distribution, such as increased total body fat, decreased muscle mass, and decreased total body water, necessitate reduction in the dosage of water- and lipid-soluble agents. Because creatinine clearance declines with age, the dosage of agents that are excreted primarily by the kidney must also be lowered to prevent toxicity. Examples include aminoglycosides, fluoroquinolones, penicillins, procainamide, lithium, angiotensin-converting enzyme inhibitors, and digoxin. A good rule of thumb to follow until creatinine clearance can be calculated is to reduce the total dose by half in frail elderly persons or in those with established renal disease. Anticholinergic agents should be used with caution because they are associated with urinary retention, heart block, constipation, dry mouth, blurred vision, sedation, and acute or chronic confusion in elderly patients.
AHA: Human Atrial Natiuretic Peptide May Reduce Reperfusion Injury
November 15th 2006CHICAGO -- Stenting for an acute myocardial infarction has a better outcome when the reperfusion is followed up with an infusion of carperitide, a human atrial natriuretic peptide, Japanese researchers reported here.
AHA: Novel Drug Effective for Hyponatremia in Heart Failure Patients
November 15th 2006CHICAGO -- Tolvaptan, an investigational selective oral vasopressin V2 -receptor antagonist, restored serum sodium concentrations in heart failure and cirrhosis patients with hyponatremia, researchers reported here.
PSA Screening Rates for Elderly Men Found Too High
November 14th 2006SAN FRANCISCO -- Older men with limited life expectancies are getting screened much too often for prostate cancer, given the potential harm that may follow a positive test versus the likelihood of benefit, researchers here reported.
Systolic and Non-Systolic Heart Failure Equal Threats
November 7th 2006ROCHESTER, Minn. -- Mortality rates for heart failure patients with preserved left ventricular ejection fraction (non-systolic) are similar to those for patients with a reduced ejection fraction (systolic). However, a higher systolic pressure on admission was a marker of better prognosis.
IASLC: Neoadjuvant Therapy Improved Complete Response in Stage III-IV Head-and-Neck Cancer
November 3rd 2006CHICAGO -- Induction therapy with Taxotere (docetaxel), Platinol (cisplatin), and 5-FU (fluorouracil) leading up to chemoradiation improved complete response in patients with inoperable stage III or IV squamous cell carcinoma of the head and neck, researchers reported here.
Mechanical Assist Plus Potent Medical Therapy Revives Failing Hearts
November 1st 2006LONDON -- For a handful of carefully selected patients, a combination of mechanical and pharmacologic interventions has reversed severe heart failure and restored normal ventricular function, investigators here reported.
Pulmonary arterial hypertension: Classification, diagnosis, and prognosis
November 1st 2006Abstract: Our understanding of the pathobiology of pulmonary arterial hypertension (PAH) has evolved considerably over the past 2 decades, with increasing recognition of the important role that aberrant vasoproliferative responses play in conjunction with disordered vasoconstriction. Classification of the many forms of PAH into categories sharing a similar pathophysiology and clinical presentations help the practicing clinician approach a complex differential diagnosis. Noninvasive tests can be used to narrow this differential but must be applied with an appreciation for their limitations. Transthoracic echocardiography is the screening tool of choice; the workup should also include chest radiography and electrocardiography. However, right heart catheterization is ultimately required to establish the diagnosis. While PAH remains a progressive and generally fatal disease, existing therapies have a significant impact on survival and new therapeutic targets offer great hope for improving the prognosis. (J Respir Dis. 2006;27(11):487-493)